Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Amycretin has some intriguing results in obesity
Amycretin, an experimental Novo Nordisk obesity pill that targets both amylin and GLP-1 receptors, spurred significant weight loss in a Phase 1 study, the company announced yesterday. Over three months, a daily dose resulted in 10.4% loss in weight; those who took two pills lost 13.1% of their body weight. By comparison, the people taking placebo experienced only 1.1% weight loss. Animal studies suggest that targeting amylin could mean less nausea and muscle loss than GLP-1, but that has yet to be proven in clinical trials.
“This is one of the most promising biologies that we’ve seen in a number of years,” Martin Lange, Novo’s head of development, told STAT. “Obviously GLP-1, specifically the longer-acting GLP-1s, have changed the field of obesity and diabetes. And when we combine the GLP-1 and the amylin biology, there is a potential to see even further weight loss.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
